Drug Profile
Cromoglicate lisetil
Alternative Names: Cromoglicate lisetil hydrochloride; Cromoglicic acid; KY-556; LP-0074; N-556Latest Information Update: 21 Jul 2015
Price :
$50
*
At a glance
- Originator Kyoto Pharmaceutical Industries
- Developer Asahi Kasei; Kyoto Pharmaceutical Industries; LEO Pharma
- Class Antiallergics; Antiasthmatics; Antihistamines; Benzopyrans; Skin disorder therapies; Small molecules
- Mechanism of Action Histamine release inhibitors; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mastocytosis; Psoriasis
- Discontinued Allergic rhinitis; Asthma; Atopic dermatitis
Most Recent Events
- 21 Jul 2015 No recent reports of development identified - Phase-II for Mastocytosis in Germany (Topical)
- 21 Jul 2015 No recent reports of development identified - Phase-II for Psoriasis in Germany (Topical)
- 01 May 2013 LEO Pharma completes a phase II trial in Psoriasis in Germany (NCT01722812)